{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:49:12Z","timestamp":1790912952819,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":801,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1111\/ajt.15811","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T10:33:24Z","timestamp":1580985204000},"page":"2457-2465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review"],"prefix":"10.1016","volume":"20","author":[{"given":"Thibaut","family":"d\u2019Izarny-Gargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-8726","authenticated-orcid":false,"given":"Antoine","family":"Durrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6847-0821","authenticated-orcid":false,"given":"Mohamad","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1111\/ajt.15811_bib1","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA."},{"issue":"12","key":"10.1111\/ajt.15811_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/TP.0000000000000375","article-title":"The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis","volume":"98","author":"Ma","year":"2014","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.15811_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaoncol.2015.5137","article-title":"Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada","volume":"2","author":"Acuna","year":"2016","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1111\/ajt.15811_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nrneph.2010.102","article-title":"Malignancy after renal transplantation: the role of immunosuppression","volume":"6","author":"Rama","year":"2010","journal-title":"Nat Rev Nephrol."},{"issue":"8","key":"10.1111\/ajt.15811_bib5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"issue":"19","key":"10.1111\/ajt.15811_bib6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"issue":"21","key":"10.1111\/ajt.15811_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.15811_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"issue":"10027","key":"10.1111\/ajt.15811_bib9","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"The Lancet."},{"issue":"4","key":"10.1111\/ajt.15811_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1111\/ajt.15811_bib11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/ajt.14349","article-title":"Belatacept-resistant rejection is associated with CD28 + memory CD8 T cells","volume":"17","author":"Mathews","year":"2017","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15811_bib12","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ajt.13613","article-title":"CD57+ CD4 T cells underlie belatacept-resistant allograft rejection","volume":"16","author":"Espinosa","year":"2016","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15811_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1600-6143.2011.03914.x","article-title":"Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys","volume":"12","author":"Medina Pestana","year":"2012","journal-title":"Am J Transplant."},{"issue":"10","key":"10.1111\/ajt.15811_bib14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response: PD-1 in alloimmunity","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.15811_bib15","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2016.02.034","article-title":"Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction","volume":"64","author":"Shi","year":"2016","journal-title":"J Hepatol."},{"issue":"8","key":"10.1111\/ajt.15811_bib16","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J Immunol."},{"issue":"1","key":"10.1111\/ajt.15811_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ki.2010.97","article-title":"Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses","volume":"78","author":"Starke","year":"2010","journal-title":"Kidney Int."},{"issue":"11","key":"10.1111\/ajt.15811_bib18","first-page":"1015","article-title":"PD-1\/PD-L1, PD-1\/PD-L2, and other co-inhibitory signaling pathways in transplantation","volume":"21","author":"del Rio","year":"2008","journal-title":"Transpl Int."},{"issue":"12","key":"10.1111\/ajt.15811_bib19","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.15811_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol."},{"key":"10.1111\/ajt.15811_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2018.03.019","article-title":"Checkpoint blockade after kidney transplantation","volume":"96","author":"Lesouhaitier","year":"2018","journal-title":"Eur J Cancer."},{"issue":"5","key":"10.1111\/ajt.15811_bib22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1111\/ajt.15811_bib23","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Annals Oncol."},{"issue":"28","key":"10.1111\/ajt.15811_bib24","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1111\/ajt.15811_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int."},{"key":"10.1111\/ajt.15811_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J Transplant."},{"issue":"6","key":"10.1111\/ajt.15811_bib27","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology."},{"key":"10.1111\/ajt.15811_bib28","doi-asserted-by":"crossref","unstructured":"Langdon S, Hughes A, Taylor MA, et al. Combination of dual mTORC1\/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. OncoImmunology. 2018;e1458810","DOI":"10.1080\/2162402X.2018.1458810"},{"issue":"1","key":"10.1111\/ajt.15811_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat Commun."},{"issue":"1","key":"10.1111\/ajt.15811_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1600-6143.2009.02859.x","article-title":"PD-1\/B7-H1 interaction contribute to the spontaneous acceptance of mouse liver allograft: B7\u2013H1 contribute liver allograft tolerance","volume":"10","author":"Morita","year":"2010","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15811_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MOT.0000000000000153","article-title":"T-cell exhaustion in allograft rejection and tolerance","volume":"20","author":"Thorp","year":"2015","journal-title":"Current Opinion Organ Transplant."},{"issue":"109","key":"10.1111\/ajt.15811_bib32","first-page":"21","article-title":"Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients","volume":"2019","author":"Rogado","year":"1990","journal-title":"Eur J Cancer Oxf Engl."},{"issue":"3","key":"10.1111\/ajt.15811_bib33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","article-title":"Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell Lung cancer","volume":"20","author":"Grangeon","year":"2019","journal-title":"Clin Lung Cancer."},{"key":"10.1111\/ajt.15811_bib34","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ."},{"issue":"3","key":"10.1111\/ajt.15811_bib35","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN- -dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol."},{"issue":"5","key":"10.1111\/ajt.15811_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1600-6143.2005.00823.x","article-title":"CTLA4 engagement is required for induction of murine liver transplant spontaneous tolerance","volume":"5","author":"Li","year":"2005","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"issue":"4","key":"10.1111\/ajt.15811_bib37","first-page":"1947","article-title":"The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival","volume":"162","author":"Judge","year":"1999","journal-title":"J Immunol Baltim Md 1950."},{"issue":"10","key":"10.1111\/ajt.15811_bib38","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:30:24Z","timestamp":1761629424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522225635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1600613522225635"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15811","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}